



Recent Advances in Management of Renal Cell Carcinoma

Guest Editors:

Dr. Anand Sharma

Prof. Dr. Nikhil Vasdev

Dr. Prantik Das

Deadline for manuscript
submissions:
closed (10 June 2025)

Message from the Guest Editors

Dear Colleagues,

First-line treatments with advanced renal cell carcinoma (aRCC) include immune check-point inhibitors used as dual-type combinations (ipilimumab and nivolumab) or tyrosine kinase inhibitors. Significant progress has been made in treatment of aRCC, and newer combinations are being investigated. Other drugs that inhibit hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF) signaling have demonstrated survival advantage. Tyrosine kinase inhibitors and mTor inhibitors have also shown an ability to inhibit aRCC growth. Key questions to answer in aRCC management include how to combine and sequence different types of therapies, as well as how to integrate new approaches in aRCC management.

The aim of this Special Issue is to define molecular and cellular targets in treating aRCC, including (1) the genetic basis and/or epigenetic mechanism of RCC; (2) drug resistance; (3) newer imaging modalities in diagnosis; (4) rare types of RCC; (5) newer drugs in aRCC treatment; (6) and real-world studies in aRCC. This Special Issue welcomes both original research articles and reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)